A human study to evaluate the effect of CKDB-317 on promoting immunity functio
- Conditions
- Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism
- Registration Number
- KCT0008686
- Lead Sponsor
- Chong Kun Dang Bio
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 100
1) Those who voluntarily decide to participate in this clinical study and signs the informed consent
2) Men and women aged 19 to 75 years inclusive at the time of signing the informed consent
3) Those who have at least respiratory infection symptoms twice for more than 12 months prior to screening
1) Those who are pregnant or lactating women
2) Those who have a history of alcohol abuse or are chronically consuming alcohol
3) Those who have a serious accompanying disease inappropriate for participation in the study
4) Those who have a history of psychiatric diseases or have a disease that interferes with participation in the study
5) Those who have a disease that can affect the immune response, such as asthma
6) Those who have a clinically significant liver disorder or kidney disorder
7) Those who regularly ingested probiotics (lactic acid bacteria, etc.) and prebiotics (e.g., dietary fiber, fructo oligosaccharide, etc.) for one month before screening
8) Those who continuously takes medicines, etc. that may affect the immune response within one month prior to screening
9) Those who have a significant infection that is active within three months prior to screening
10) Those who are required to take drugs continuously that are deemed to affect the results of the study
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ature Killer cell activity
- Secondary Outcome Measures
Name Time Method Monocyte;PSS(Perceived Stress Scale);WURSS-21: Wisconsin Upper Respiratory Symptom Survey-21